Carlsmed (CARL) Cost of Revenue (2024 - 2026)

Carlsmed (CARL) has 3 years of Cost of Revenue data on file, last reported at $7.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 208.85% year-over-year to $7.9 million; the trailing twelve-month figure through Mar 2026 stood at $35.8 million (up 49.89% YoY), and the FY2025 full-year result was $26.4 million, up 23.07% from the prior year.
• Cost of Revenue for Q1 2026 stood at $7.9 million, down from $17.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $17.9 million in Q4 2024 and bottomed at $840000.0 in Q2 2025.
• The 3-year median for Cost of Revenue is $5.2 million (2025), against an average of $7.5 million.
• Peak annual rise in Cost of Revenue reached 392.82% in 2025, while the deepest fall reached 44.7% in 2025.
• A 3-year view of Cost of Revenue shows it stood at $17.9 million in 2024, then dropped by 2.13% to $17.5 million in 2025, then tumbled by 54.97% to $7.9 million in 2026.
• The last three Cost of Revenue figures came in at $7.9 million (Q1 2026), $17.5 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.

Peer Comparison